Source:http://linkedlifedata.com/resource/pubmed/id/11815491
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2002-3-7
|
pubmed:abstractText |
In a cross-sectional study, we assessed beta-cell function and insulin sensitivity index (ISI) with hyperglycemic clamps (10 mmol/l) in 24 subjects with impaired fasting glycemia (IFG, fasting plasma glucose [FPG] between 6.1 and 7.0 mmol/l), 15 type 2 diabetic subjects (FPG >7.0 mmol/l), and 280 subjects with normal fasting glycemia (NFG, FPG <6.1 mmol/l). First-phase insulin release (0-10 min) was lower in IFG (geometric mean 541 pmol/l.10 min; 95% confidence interval [CI] 416-702 pmol/l.10 min) and in type 2 diabetes (geometric mean 376 pmol/l.10 min; 95% CI 247-572 pmol/l.10 min) than NFG (geometric mean 814 pmol/l.10 min; 95% CI 759-873 pmol/l.10 min) (P < 0.001). Second-phase insulin secretion (140-180 min) was also lower in IFG (geometric mean 251 pmol/l; 95% CI 198-318 pmol/l; P = 0.026) and type 2 diabetes (geometric mean 157 pmol/l; 95% CI 105-235 pmol/l; P < 0.001) than NFG (geometric mean 295 pmol/l; 95% CI 276-315 pmol/l). IFG and type 2 diabetic subjects had a lower ISI (0.15 plus minus 0.02 and 0.16 plus minus 0.02 micromol/kg fat-free mass [FFM]/min/pmol/l, respectively) than NFG (0.24 plus minus 0.01 micromol/kg FFM/min/pmol/l, P < 0.05). We found a stepwise decline in first-phase (and second-phase) secretion in NFG subjects with progressive decline in oral glucose tolerance (P < 0.05). IFG subjects with impaired glucose tolerance (IGT) had lower first-phase secretion than NFG subjects with IGT (P < 0.02), with comparable second-phase secretion and ISI. NFG and IFG subjects with a diabetic glucose tolerance (2-h glucose >11.1 mmol/l) had a lower ISI than their respective IGT counterparts (P < 0.05). We conclude that the early stages of glucose intolerance are associated with disturbances in beta-cell function, while insulin resistance is seen more markedly in later stages.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0012-1797
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
51 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S265-70
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11815491-Adult,
pubmed-meshheading:11815491-Blood Glucose,
pubmed-meshheading:11815491-Cross-Sectional Studies,
pubmed-meshheading:11815491-Diabetes Mellitus, Type 2,
pubmed-meshheading:11815491-Fasting,
pubmed-meshheading:11815491-Female,
pubmed-meshheading:11815491-Glucose Tolerance Test,
pubmed-meshheading:11815491-Humans,
pubmed-meshheading:11815491-Hyperglycemia,
pubmed-meshheading:11815491-Insulin Resistance,
pubmed-meshheading:11815491-Islets of Langerhans,
pubmed-meshheading:11815491-Linear Models,
pubmed-meshheading:11815491-Male,
pubmed-meshheading:11815491-Middle Aged
|
pubmed:year |
2002
|
pubmed:articleTitle |
Disturbances in beta-cell function in impaired fasting glycemia.
|
pubmed:affiliation |
Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands. t.w.vanhaeften@azu.nl
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study
|